UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 597.9	$ 645.5
Accounts receivable, net	471.7	472.7
Inventories	858.8	800.1
Assets held for sale	0.0	1.4
Other current assets	204.6	193.5
Total current assets	2,133.0	2,113.2
Property, plant and equipment, net	510.9	487.0
Goodwill	527.3	457.6
Intangible assets, net	298.5	270.9
Other long-term assets	294.2	283.1
Total assets	3,763.9	3,611.8
Current liabilities:
Current portion of long-term debt	120.1	18.7
Accounts payable	196.2	178.4
Deferred revenue and customer advances	397.8	370.2
Other current liabilities	334.4	347.0
Total current liabilities	1,048.5	914.3
Long-term debt	1,109.0	1,200.5
Other long-term liabilities	395.6	365.2
Commitments and contingencies (Note 14)
Redeemable noncontrolling interests	12.0	6.1
Shareholders' equity:
Preferred stock, $0.01 par value 5,000,000 shares authorized, none issued or outstanding	0.0	0.0
Common stock, $0.01 par value 260,000,000 shares authorized, 175,443,006 and175,389,586 shares issued and 146,761,246 and 147,023,144 shares outstanding at March 31, 2023 and December 31, 2022, respectively	1.7	1.7
Treasury stock, at cost, 28,681,760 and 28,366,442 shares at March 31, 2023 and December 31, 2022, respectively	(1,107.2)	(1,085.0)
Accumulated other comprehensive income, net of tax	29.6	14.8
Other shareholders' equity	2,256.2	2,182.3
Total shareholders' equity attributable to Bruker Corporation	1,180.3	1,113.8
Noncontrolling interests in consolidated subsidiaries	18.5	11.9
Total shareholders' equity	1,198.8	1,125.7
Total liabilities, redeemable noncontrolling interests and shareholders' equity	$ 3,763.9	$ 3,611.8